Recent work showed an in vivo expansion of recipient regulatory T cells before MHC-disparate allogeneic HCT reduces the risk of GvHD without preventing the reconstitution of antiviral CD8+ effector T cells [132]. The gene discussed is CD8A; the disease is graft versus host disease.